J.L. Carreras-Delgado
Complutense University of Madrid
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by J.L. Carreras-Delgado.
European Journal of Nuclear Medicine and Molecular Imaging | 2010
Felisa Jiménez-Requena; Roberto Delgado-Bolton; Cristina Fernández-Pérez; Sanjiv S. Gambhir; Judy Schwimmer; José M. Pérez-Vázquez; J.L. Carreras-Delgado
IntroductionThe aim of this study was to perform a systematic review of the literature to evaluate the accuracy of FDG-PET in staging and restaging of cutaneous melanoma.MethodsSystematic methods were used to identify, select, and evaluate the methodologic quality of the studies as well as to summarize the overall findings of sensitivity and specificity. The search strategy consisted of identifying studies published between 2000 and 2006. Inclusion criteria were studies that evaluated the diagnostic performance of FDG-PET in staging/restaging of cutaneous melanoma. The results were compared and pooled with a meta-analysis published previously that included studies published until 1999. The meta-analysis included 95% confidence intervals (CI) of sensitivity, specificity, likelihood-ratio (LR), and diagnostic-odds-ratio (DOR).ResultsThe quantitative meta-analysis included 24 studies that were analysed in two groups: eight studies were included only in the regional staging analysis (group I), 13 studies were included only in the detection of distant metastases analysis (group II), and three studies were included in both analyses. Compliance with the methodologic-quality criteria was acceptable. We analysed the results of data presented in patients, lesions, basins, lymph-nodes, areas, and scans. Regarding the performance of FDG-PET in the detection of metastases, the pooled studies presented homogeneity for the negative-LR (0.15; 95% CI, 0.10–0.22) when analyzing lesions. When analyzing scans, there was global homogeneity for specificity (0.86; 95% CI, 0.77–0.92), positive-LR (5.86; 95% CI, 3.64–9.43), and DOR (37.89; 95% CI, 15.80–90.86). The pooled studies presented heterogeneity for the other items analysed. Regarding the detection of regional metastases, when analyzing lymph-nodes there was global homogeneity for specificity (0.99; 95% CI, 0.97–0.99; P = 0.101). The meta-regression evidenced that the variable that most influenced the DOR of the different studies and that can explain the heterogeneity was the year of publication; this may be related to the evolution of PET technology and an improvement of sensitivity/specificity.ConclusionFDG-PET is not useful in the evaluation of regional metastases, as it does not detect microscopic disease. However, FDG-PET could be useful in the detection of distant metastases, and could suggest its utility in the management of patients with cutaneous melanoma.
European Journal of Nuclear Medicine and Molecular Imaging | 2016
A. Jiménez-Ballvé; M.J. Pérez-Castejón; Roberto Delgado-Bolton; Cristina Sánchez-Enrique; Isidre Vilacosta; David Vivas; Carmen Olmos; Manuel E. Fuentes Ferrer; J.L. Carreras-Delgado
PurposeThe diagnosis of prosthetic valve (PV) infective endocarditis (IE) and infection of cardiac implantable electronic devices (CIEDs) remains challenging. The aim of this study was to assess the usefulness of 18F-FDG PET/CT in these patients and analyse the interpretation criteria.MethodsWe included 41 patients suspected of having IE by the Duke criteria who underwent 18F-FDG PET/CT. The criteria applied for classifying the findings as positive/negative for IE were: (a) visual analysis of only PET images with attenuation-correction (AC PET images); (b) visual analysis of both AC PET images and PET images without AC (NAC PET images); (c) qualitative analysis of NAC PET images; and (d) semiquantitative analysis of AC PET images. 18F-FDG PET/CT was considered positive for IE independently of the intensity and distribution of FDG uptake. The gold standard was the Duke pathological criteria (if tissue was available) or the decision of an endocarditis expert team after a minimum 4 months follow-up.ResultsWe studied 62 areas with suspicion of IE, 28 areas (45 %) showing definite IE and 34 (55 %) showing possible IE. Visual analysis of only AC PET images showed poor diagnostic accuracy (sensitivity 20 %, specificity 57 %). Visual analysis of both AC PET and NAC PET images showed excellent sensitivity (100 %) and intermediate specificity (73 %), focal uptake being more frequently associated with IE. The accuracy of qualitative analysis of NAC PET images depended on the threshold: the maximum sensitivity, specificity and accuracy achieved were 88 %, 80 %, 84 %, respectively. In the semiquantitative analysis of AC PET images, SUVmax was higher in areas of confirmed IE than in those without IE (∆SUVmax 2.2, p < 0.001). When FDG uptake was twice that in the liver, IE was always confirmed, and SUVmax 5.5 was the optimal threshold for IE diagnosis using ROC curve analysis (area under the curve 0.71).ConclusionThe value of 18F-FDG PET/CT in the diagnosis of suspected IE of PVs and CIEDs is highly dependent on patient preparation and the method used for image interpretation. Based on our results, the best method is to consider a study positive for IE when FDG uptake is present in both AC PET and NAC PET images.
Revista Espanola De Medicina Nuclear | 2016
A. Jiménez-Ballvé; M. García García-Esquinas; O. Salsidua-Arroyo; A. Serrano-Palacio; José Ángel García-Sáenz; A. Ortega Candil; M.E. Fuentes Ferrer; C. Rodríguez Rey; J.M. Román-Santamaría; Fernando Salvador Moreno; J.L. Carreras-Delgado
OBJECTIVE To determine whether metabolic tumour volume (MTV) and total lesion glycolysis (TLG) are able to predict recurrence risk in locally advanced breast cancer (LABC) patients. MATERIAL AND METHODS Retrospective study of LABC patients who undertook neoadjuvant, local and adjuvant treatment and follow up. A 18F-FDG PET/CT study for initial staging was performed analysing in this study different metabolic parameters (MTV, TLG, SUVmax and SUVmed) both in the primary tumour (T) as well as in axillary nodes (N) and whole-body (WB). RESULTS Forty females were included between January 2010-2011; follow up until January 2015 was completed. The average follow-up was 46 months. Twenty percent presented recurrence: local disease (n=2) and distant metastasis (n=6); 3 patients died (38% of the patients which recurred and 7.5% from the total). SUVmax, MTV and TLG, in T, N and WB, were higher in those patients with recurrence. The MTV and TLG parameters in the tumour (T) were related to the recurrence rate (P=.020 and P=.028, respectively); whereas SUVmax in the lymph nodes (N) was significantly related (P=.008) to the recurrence rate. The best cut-off points to predict recurrence where: MTV T ≥19.3cm3, TLG T≥74.4g and SUVmax N≥13.8, being 10-12 times more likely to recidivate when these thresholds where exceeded. Tumour grade was the only clinical-pathological variable which was related to recurrence probability (p=.035). CONCLUSIONS In this study of LABC patients the metabolic parameters which have a better relationship with recurrence rate are: MTV and TLG in the primary tumour, SUVmax in the regional lymph node disease and whole-body PET data.
Revista Espanola De Medicina Nuclear | 2017
C. Riola-Parada; A. Jiménez-Ballvé; A. Serrano-Palacio; M.N. Cabrera-Martín; J.M. Brenes-Sánchez; J.L. Carreras-Delgado
Revista Espanola De Medicina Nuclear | 2015
A. Jiménez-Ballvé; A. Serrano-Palacio; J.A. García-Sáenz; A. Ortega Candil; O. Salsidua-Arroyo; J.M. Román-Santamaría; A. Pelayo Alarcón; M.E. Fuentes Ferrer; J.L. Carreras-Delgado
Revista Espanola De Medicina Nuclear | 2017
C. Riola-Parada; A. Jiménez-Ballvé; A. Serrano-Palacio; M.N. Cabrera-Martín; J.M. Brenes-Sánchez; J.L. Carreras-Delgado
Revista Espanola De Medicina Nuclear | 2016
A. Jiménez-Ballvé; M.J. Pérez-Castejón; C. Sánchez-Enrique; I. Vilacosta; L. Lapeña-Gutiérrez; J.L. Carreras-Delgado
Revista Espanola De Medicina Nuclear | 2016
A. Jiménez-Ballvé; M.J. Pérez-Castejón; C. Sánchez-Enrique; I. Vilacosta; L. Lapeña-Gutiérrez; J.L. Carreras-Delgado
Revista Espanola De Medicina Nuclear | 2016
A. Ortega-Candil; C. Rodríguez-Rey; R. Cano-Carrizal; E. Cala-Zuluaga; J.L. González Larriba; A. Jiménez-Ballvé; M.E. Fuentes-Ferrer; M.N. Cabrera-Martín; M.J. Pérez-Castejón; M. García García-Esquinas; L. Lapeña-Gutiérrez; J.L. Carreras-Delgado
Revista Espanola De Medicina Nuclear | 2015
A. Jiménez-Ballvé; A. Serrano-Palacio; J.A. García-Sáenz; A. Ortega Candil; O. Salsidua-Arroyo; J.M. Román-Santamaría; A. Pelayo Alarcón; M.E. Fuentes Ferrer; J.L. Carreras-Delgado